Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

In an interview with CancerNetwork®, Thomas G. Martin spoke about how the approval of ciltacabtagene autoleucel will likely dramatically impact the standard of care for patients with relapsed/refractory multiple myeloma.

Patients with heavily pretreated relapsed/refractory multiple myeloma may now receive treatment with ciltacabtagene autoleucel following its approval by the FDA.

Thomas Martin, MD, spoke about how the approval of ciltacabtagene autoleucel for patients with relapsed/refractory multiple myeloma may change the standard of care in this setting.

Thomas Martin, MD, spoke about how to increase response durability with ciltacabtagene autoleucel for patients with heavily pretreated multiple myeloma.